BioCentury
ARTICLE | Clinical News

Clearside discontinues combo therapy for retinal vein occlusion

November 9, 2018 5:51 PM UTC

Clearside Biomedical Inc. (NASDAQ:CLSD) discontinued development of Xipere (formerly CLS-TA) plus Eylea aflibercept to treat macular edema following retinal vein occlusion (RVO) after the combination missed the primary endpoint in the Phase III SAPPHIRE trial.

On the 460-patient trial's primary endpoint, Clearside said about 50% of patients in both the Xipere plus intravitreal Eylea and Eylea alone arms achieved a ≥15 letter improvement from baseline in best corrected visual acuity (BCVA) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart at eight weeks. The company will also discontinue the Phase III TOPAZ trial of Xipere plus an anti-VEGF agent in the indication...

BCIQ Company Profiles

Clearside Biomedical Inc.

BCIQ Target Profiles

Glucocorticoid receptor (GCCR)